Acarix Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
ACARIX
- Share Price
-
$0.02
- (As of Friday Closing)
Acarix General Information
Description
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
Contact Information
Website
www.acarix.comCorporate Office
- C/o Regus Hyllie
- Hyllie Boulevard 34, 5TR
- 215 32 Malmo
- Sweden
Corporate Office
- C/o Regus Hyllie
- Hyllie Boulevard 34, 5TR
- 215 32 Malmo
- Sweden
Acarix Stock Performance
As of 13-Nov-2026, Acarix’s stock price is $0.02. Its current market cap is $21.7M with 1.24B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $0.02 - $0.04 | $21.7M | 1.24B | 1.38M |
Acarix Financials Summary
As of 30-Sep-2026, Acarix has a trailing 12-month revenue of $1.04M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 21,161 | 30,116 | 20,244 | 13,079 |
| Revenue | 1,035 | 749 | 586 | 587 |
| EBITDA | (3,611) | (4,552) | (5,961) | (7,023) |
| Net Income | (4,010) | (4,895) | (6,258) | (7,323) |
| Total Assets | 4,143 | 5,252 | 7,320 | 6,292 |
| Total Debt | 0 | 0 | 0 | 0 |
Acarix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Acarix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Acarix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Acarix Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Acarix ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
Acarix Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Caire Medical Germany | Koln, Germany | 2016 |
Acarix FAQs
-
When was Acarix founded?
Acarix was founded in 2009.
-
Where is Acarix headquartered?
Acarix is headquartered in Malmo, Sweden.
-
What is the size of Acarix?
Acarix has 8 total employees.
-
What industry is Acarix in?
Acarix’s primary industry is Diagnostic Equipment.
-
Is Acarix a private or public company?
Acarix is a Public company.
-
What is Acarix’s stock symbol?
The ticker symbol for Acarix is ACARIX.
-
What is the current stock price of Acarix?
As of 13-Nov-2026 the stock price of Acarix is $0.02.
-
What is the current market cap of Acarix?
The current market capitalization of Acarix is $21.7M.
-
What is Acarix’s current revenue?
The trailing twelve month revenue for Acarix is $1.04M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
